Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
BMS-J&J blood thinner fails phase 3, denting blockbuster hopes
The partners stopped the phase 3 early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.
Nick Paul Taylor
Nov 14, 2025 8:10am
Neuphoria, reeling from ph. 3 fail, mulls buyout from investor
Nov 11, 2025 8:40am
Neurocrine-Takeda psychiatry pact suffers another phase 2 fail
Nov 11, 2025 6:25am
AnaptysBio abandons rosnilimab for UC after phase 2 fail
Nov 10, 2025 10:05am
Amgen halts gastric cancer trial after subpar efficacy analysis
Nov 5, 2025 4:35am
Harmony halts genetic disease program after phase 3 failure
Nov 4, 2025 12:45pm
